GSK ovarian cancer drug Zejula gets USFDA nod for wider use Medical Dialogues Bureau24 Oct 2019 10:00 AM ISTZejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million...
GSK drug Zejula helps ovarian cancer patients live longer in late-stage study Medical Dialogues Bureau16 July 2019 9:26 AM ISTGSK bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian...
GSK reports positive data from trial of cancer drug Dostarlimab Garima21 March 2019 9:15 AM ISTGSK said it would apply for marketing approval for Dostarlimab in endometrial cancer at the end of 2019.New Delhi: GlaxoSmithKline said on Tuesday a...
FDA approves intravenous version of Tesaro drug for chemotherapy nausea Ruby Khatun Khatun28 Oct 2017 9:44 AM ISTTesaro Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) approved an intravenous version of its drug to treat...
